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Abstract
Background: In the absence of head-to-head trials, indirect comparisons of randomized placebo-controlled trials
may provide a viable option to assess relative efficacy. The purpose was to estimate the relative efficacy of
reduction of fractures in post-menopausal women, and to assess robustness of the results.
Methods: A systematic literature review of multiple databases identified randomized placebo-controlled trials with
nine drugs for post-menopausal women. Odds ratio and 95% credibility intervals for the rates of hip, non-vertebral,
vertebral, and wrist fractures for each drug and between drugs were derived using a Bayesian approach. A drug
was ranked as the most efficacious if it had the highest posterior odds ratio, or had the highest effect size.
Results: 30 studies including 59,209 patients reported fracture rates for nine drugs: alendronate (6 studies),
denosumab (1 study), etidronate (8 studies), ibandronate (4 studies), raloxifene (1 study), risedronate (7 studies),
strontium (2 study), teriparatide (1 study), and zoledronic acid (1 study). The drugs with the highest probability of
reducing non-vertebral fractures was etidronate and teriparatide while the drugs with the highest probability of
reducing vertebral, hip or wrist fractures were teriparatide, zoledronic acid and denosumab. The drugs with the
largest effect size for vertebral fractures were zoledronic acid, teriparatide and denosumab, while the drugs with
the highest effect size for non-vertebral, hip or wrist fractures were alendronate or risedronate. Estimates were
consistent between Bayesian and classical approaches.
Conclusion: Teriparatide, zoledronic acid and denosumab have the highest probabilities of being most efficacious
for non-vertebral and vertebral fractures, and having the greatest effect sizes. The estimates from indirect
comparisons were robust to differences in methodology.
Background
Osteoporosis defined by low Bone Mineral Density
(BMD) (i.e., 2.5 standard deviations below peak gender
specific BMD), is a progressive disease with high preva-
lence affecting 1 in 3 women and 1 in 8 men by the
time they reach 90 years of age [1]. The major concern
with low BMD is the high risk of fractures to non-ver-
tebral bones such as the wrist or to the hip. A hip frac-
ture may require extended hospital stay, surgical repair
and rehabilitation therapy, and is associated with
increased risk of death [2]. In addition, osteoporosis can
lead to vertebral fractures which are identified by clini-
cal assessment through decreased patient height (i.e.,
stooped posture) or with compressed spinal vertebra
that can be radiologically assessed [3].
To reduce the risk of fractures due to osteoporosis,
drugs have been introduced to reduce the rate of bone
loss and to increase the strength of the bones. The first
bisphosphonate available in Canada was etidronate in
1995 followed by alendronate in 1998. In 2005, alendro-
nate became generic, which introduced a large increase
in the uptake of these drugs. In Canada in 2010 about
9% of the population age 50 years and over were receiv-
ing an osteoporosis drug. These drugs include the
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any medium, provided the original work is properly cited.bisphosphonates (alendronate, etidronate, risedronate or
ibandronate), Selective Estrogen Receptor Modulators
(raloxifene) and anabolic agents (teriparatide). All of
these have shown to be effective in reducing the rate of
fractures relative to placebo [4]. Recent additions to
pharmacotherapy for osteoporosis include denosumab,
strontium and zoledronic acid. Accordingly, it would be
clinically important to know an estimate of the relative
treatment efficacy or ranking of the most efficacious
drugs. A major gap in the evidence to identify the most
efficacious drugs is the lack of randomized active-con-
trolled trials, i.e., direct treatment comparison (DTC)
evidence [4].
DTC evidence for osteoporosis is absent because such
later stage III trials are more complex, expensive, and
require larger sample sizes than earlier phase II rando-
mized placebo-controlled trials (RPCT) [5]. Meanwhile,
osteoporosis drugs have been approved for use or listed
under reimbursement formularies based on RPCT evi-
dence, even though there are skeptics on the benefits of
RPCTs for estimating relative efficacy compared to cur-
rently available drugs and that RPCTs are unethical. In
a recent New England Journal of Medicine debate, Stein
[6] argued that RPCTs are unethical because of the
withholding of proven therapies in the placebo alloca-
tion, while Rosen [7] argued that the therapies are only
proven in high risk patients (prior fracture, BMD < -3,
or higher fracture risk assessment) and the inclusion cri-
teria that possess true equipoise should only include
individuals who are at low risk or are non-responsive to
mild therapies. However in Canada the Tri-Council Pol-
icy Statement on the Ethical Conduct for Research
Involving Humans suggest that RPCTs are acceptable to
establish existence of effect and adverse events of drugs
with new pharmacological mechanisms [8]. In the
absence of DTC evidence, indirect treatment compari-
sons (ITC) might be a promising technique that allows
the synthesis of available RPCT evidence to make a sug-
gestion on the effect of DTC [9]. The theoretical foun-
dations of the ITC method were provided in 1997 by
Bucher [10] for the pair wise division of odds ratios to
produce a common odds ratio thereafter referred to as
the Bucher Method (i.e., for 2 drugs A and C and pla-
cebo B, the odds ratio of A/B divided by odds ratio C/B
produces an odds ratio of A/C). While DTC is the high-
est level of clinical evidence, there exists the rationale to
use ITC analysis where DTC is absent and not likely to
be forthcoming [10]. Even if DTC evidence was avail-
able, ITC evidence based on other trials may be useful
because of differences in patient characteristics and
study characteristics such as length of follow-up [11].
In the absence of DTC evidence for osteoporosis
drugs, two ITC analyses have been conducted to assess
the relative efficacy at reducing the rates of fractures in
post-menopausal women [12,13]. The first using a Baye-
sian analysis that looked at seven studies including four
drugs zoledronic acid (1 study), alendronate (3 studies),
ibandronate (1 study) and risedronate (2 studies). this
indicated that zoledronic acid had the highest efficacy in
preventing vertebral fractures [12]. The second and
more comprehensive analysis included eight RPCTs
which was an update involving the above four medica-
tions adding etidronate (1 study). Of the five medica-
tions analyzed zoledronic acid had the highest efficacy
in preventing vertebral and hip fractures while risedro-
nate had the highest efficacy in reducing non-vertebral
non-hip fractures [13].
We believe we can build on this pioneering work.
First, nine drugs are currently available in Canada, Eur-
opean or the United States for use with osteoporosis.
The nine drugs include the above five (zoledronic acid,
alendronate, ibandronate, and risedronate) in the recent
ITC analysis plus four more drugs that were not pre-
viously included (denosumab, raloxifene, strontium, and
teriparatide). In addition, there are key differences in
patient characteristics across the studies such as age,
BMD, and fracture history. Further adjustment for these
factors might affect estimates of the relative efficacy
between treatments.
The purpose of this paper is to build on the previous
estimation of relative efficacy between osteoporosis
drugs for the prevention of fractures. First, we update
the literature on osteoporosis drugs to include recent
additions in pharmacotherapy and recent RPCTs by
conducting a multiple database systematic literature
review. Second, we estimate the relative efficacy of redu-
cing fractures of each drug versus placebo and between
the drugs with Bayesian ITC analysis. Third, we conduct
the ITC analysis using Bucher’s method, a classical ana-
lysis approach. Finally, we estimated the relative efficacy
after adjustment for baseline patient characteristics.
Methods
Literature Search
An electronic search of the following databases
restricted to English was conducted from January 1990
to October 2009, and the search was continually
updated by alerts until September 2010: EMBASE, Med-
line, Medline in Process, and Cochrane Database for
Systematic Reviews, Evidence Based Reviews-American
College of Physicians Journal, National Health Service
(NHS) Database of Assessment of Reviews and Effective-
ness (DARE), CINAHL. Specific searches were devel-
oped for each database with the aid of professional
librarian and were based on MeSH headings and key-
words: osteoporosis, fractures, and bones. Methodologi-
cal filters for randomization were applied to Medline
and EMBASE (see additional file 1 for the search
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each article that was identified. Following the literature
searches, all citations were incorporated into Reference
Manager citation database software [14] and duplicates
were identified and removed.
The inclusion criteria was that each article must have;
1) one of the nine osteoporosis drugs: alendronate,
denosumab, etidronate, ibandronate, raloxifene, risedro-
nate, strontium, teriparatide, or zoledronic acid, 2) have
a RPCT design, 3) have only post-menopausal women
as an inclusion criterion, and 4) report the rate of frac-
tures as a primary or secondary outcome. Studies were
excluded if they were studies that combined different
trials, were subgroup analysis, or the outcomes were not
fractures such as BMD.
Selection of trials for inclusion and data abstraction
At the first level of screening of the publications, the
titles and abstracts of the citations that were obtained
from the search strategy were reviewed for relevance
and inclusion for full-text review. Of these articles pas-
sing to level two, the articles were reviewed as full text
for relevance. After inclusion, data was abstracted to
pre-specified abstraction forms and then entered into
Microsoft Excel and the Bayesian meta-analysis software
WinBUGS (Bayesian inference Using Gibbs Sampling
for Windows) [15]. For the literature retrieved based on
the targeted review for systematic reviews and meta-
analysis, the same 4 inclusion criteria applied. Literature
screening was conducted by two independent reviewers,
with consensus reached on all discrepancies.
Outcomes
The main outcomes were the rates of vertebral, non-ver-
tebral, hip and wrist fractures. In addition, study charac-
teristics (country, numbers of study centres, and patient
f o l l o wu pi ny e a r s )a n db a s e l i n ep a t i e n tc h a r a c t e r i s t i c s
(age in years, years since menopause, BMD of the hip
reported as g/cm
2, and history of fractures) were
abstracted. Data abstraction was verified by a second
independent reviewer. For each outcome, the unadjusted
odds ratio for each drug versus placebo were estimate
along with its 95% CrI. In addition, the adjusted for
fracture between each drug comparator was estimated
along with its 95% CrI (i.e., Odds ratio of A/B = odd
ratio (A/B) divided by odds ratio of C/B).
Primary Statistical Analysis: Bayesian ITC estimate of
relative efficacy versus placebo and other drugs
ITC was conducted for the unadjusted analysis using
Bayesian methods in WinBUGS software version 1.4.3
[15], which performs Bayesian analysis using Markov
Chain Monte Carlo methods (see additional file 2 for
software code). We reported the analysis according to
the Reporting Of Bayes used in clinical STudies
(ROBUST) criteria [16]. The outcome estimated was the
mean and the 95% credibility interval of the posterior
distribution of the odds ratio of the rate of fracture ver-
sus placebo and other drugs, for each fracture. For the
Bayesian analysis, priors were predefined for the mean
log odds ratio as a normal distribution with mean zero,
and precision 0.001 representing weak prior informa-
tion. Weak priors were chosen so that the final esti-
mates for odds ratios are driven by the data, and not by
any assumption made. For each outcome, we performed
100,000 simulations discarding the first 50,000 simula-
tions to allow burn-in; two chains were run simulta-
neously. Convergence was assessed using all of the
Geweke, Raftery-Lewis, Gelman-Rubin and Heidelber-
ger-Welch tests. To make a comparison of all drugs to
each in order to determine the most effect efficacious
drug, the proportion of Markov chain iterations in
which a drug had the highest odds ratio represented the
probability of that drug being ranked the most effica-
cious. In addition, the effect size was estimated for each
drug versus placebo, where effect size was defined as the
ratio of the odds ratio for fracture of placebo versus
drug divided by the standard error of the estimate of
the odds ratio. A higher effect size indicates the drug
has lower odds for fractures than placebo and/or that
the standard error is small. Software code for WinBUGS
is provided in appendix 2.
Assessing robustness: homogeneity and consistency of
evidence
A number of steps were taken to assess the integrity of
the ITC analysis [10,17-20]. The assessments included;
1) assessing homogeneity in meta-analysis of each com-
parator and across comparators, and 2) checking the
consistency of the ITC analysis between Bayesian and
classical software, and 3) checking the consistency of
the ITC analysis to DTC if available. If there is homoge-
neity within drugs and across drugs, and the ITC evi-
dence is consistent across methodologies or with DTC
evidence, then the ITC evidence in considered strong
and free of bias [19].
Homogeneity with each drug and across each drug
was assessed with Review Manager 5 software [21]. Het-
erogeneity was assessed with I
2 with greater than 50%
being moderate heterogeneity and greater than 70%
being considerable heterogeneity as suggested by the
Cochrane Handbook of Systematic Reviews [22]. Consis-
tency of evidence was assessed by comparing the results
of the Bayesian analysis to free software specifically cre-
ated for ITC analysis [23]. This software package for
ITC was released by the Canadian Agency for Drugs
and Technologies in Health (CADTH) [24], a national
agency in Canada that provides evidence based decisions
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level governments. Checking consistency of ITC evi-
dence versus DTC evidence was conducted by a search
for meta-analysis of DTC evidence.
Adjustment for difference in baseline characteristics
Lastly, we checked whether differences in patient char-
acteristics across drugs contributed to the relative effi-
cacy estimates in the ITC analysis. We estimated the
odds ratios for fracture reduction with classical meta-
analysis with meta-regression with the log of the odds
ratio as the dependent variable, and dummy variables
were added for each of the drugs. Following the unad-
justed results, we adjusted the ITC estimates with meta-
regression to include the age in years, BMD in g\cm
2,
percent of subjects with history of a vertebral fracture.
Meta-regression was conducted with STATA version
11.0 using the command metareg.
Results
Based on the literature review, 30 RPCTs that investi-
gated the effect of drugs on the rate of fractures were
identified. The results of the screening process are pro-
v i d e di nt h eP R I S M Ad i a g r a m[ 2 5 ]i nF i g u r e1a n dt h e
descriptions of the included studies are presented in
Table 1. For the 9 drugs, 6 studies were for alendronate
[26-31], 1 study for denosumab [32], 8 studies for eti-
dronate [33-40], 4 studies for ibandronate [41-44], 1
study for raloxifene [45], 6 studies for risedronate
[46-51], 2 studies for strontium [52,53], 1 for teripara-
tide [54], and 1 for zoledronic Acid [55]. The partici-
pants in the studies included 59,209 patients. The
participants had a mean age ranging in studies between
52 and 72 years of age, years since menopause ranged
from 2.7 to 31.9 years, and the study durations were
from 1 to 4 years. Baseline BMD in the hip ranged from
0.28 to 1.08 and the percentage of participants that had
previous vertebral fractures were from 0% to 100%.
Bayesian ITC estimate of relative efficacy versus placebo
and other drugs
The estimates of relative efficacy of each drug versus pla-
cebo in the Bayesian meta-analysis is reported in table 2.
For non-vertebral fractures, only alendronate OR = 0.81
(95%CrI: 0.66, 0.96) and risedronate OR = 0.77 (95%CrI:
0.60, 0.91) had significant reduction. Etidronate had the
highest probability of being most efficacious (0.41) along
with teriparatide (0.41). All other drugs had less than
0.10 probability of being most efficacious. However, the
drugs with the highest effect size were Risedronate (16.4)
and Alendronate (16.1), but these effect sizes were smal-
ler than the effect sizes for vertebral fractures. Based on
the probabilities of being most efficacious, etidronate and
zoledronic acid are the most efficacious drugs. However
since etidronate does not have significant effect versus
placebo, teriparatide is the most efficacious drug. In the
ITC head-to-head analysis (Table 3) there is not enough
evidence to detect differences in efficacy between any of
the drugs for non-vertebral fractures, although teripara-
tide, zoledronic acid and denosumab have the lowest
numbers need to treat to prevent a non-vertebral fracture
versus the other drugs.
For vertebral fractures, all drugs except etidronate had
significant reductions in the odds of a fracture. The drugs
with the highest probability of being most efficacious are
teriparatide (0.30), zoledronic acid (0.40) and denosumab
(0.20). However, the drugs with the highest effect size
were also teriparatide (29.8), zoledronic acid (66.2) and
denosumab (53.6) based on probabilities and effect size
the three drugs are most efficacious. In addition, these 3
drugs also had the lowest number needed to treat versus
the other drugs (Table 3). In the ITC head-to-head analy-
sis, teriparatide had significant reduction in vertebral frac-
ture versus ibandronate and raloxifene, while denosumab
had significant reductions versus alendronate, raloxifene,
and risedronate. Zoledronic acid had significant reductions
versus alendronate, raloxifene, and risedronate (Table 3).
For hip fractures, only alendronate has a significant
reduction in relative rate of fractures (OR = 0.59 (95%CrI:
0.29 to 0.99). The drugs that had the highest probability of
most efficacious were teriparatide (0.44) and etidronate
(0.19). The drugs with the highest effect size were alendro-
nate (9.49) and risedronate (5.71). Based on probabilities
and effect size it is unclear which drug might be ranked
most efficacious out of the choices of teriparatide or alen-
dronate. In the ITC head-to-head analysis, the relative effi-
cacy of teriparatide versus alendronate was OR = 1.35
(95%CrI: 0.07, 5.71) which is a non-significant finding.
There were no drugs that had a significant benefit for hip
fractures versus the other drugs (Table 3).
For wrist fractures, there were no drugs that a signifi-
cant protective effect versus placebo, although no wrist
fracture data was available for denosumab, ibandronate
or zoledronic acid. The drugs that had the highest prob-
ability of most efficacious were teriparatide (0.41) and
risedronate (0.22). The drugs with the highest effect size
were alendronate (1.80) and risedronate (1.37), although
the magnitude of the effect size was considerably lower
than for other fractures. Based on probabilities and
effect size it is unclear which drug might be ranked
most efficacious out of the choices of teriparatide or
alendronate. In the ITC head-to-head analysis, the rela-
tive efficacy of teriparatide versus alendronate was OR =
1.69 (95%CrI: 0.04, 8.09) which is a non-significant find-
ing. There were no drugs that had a significant benefit
for wrist fractures versus the other drugs (Table 3).
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evidence
There was no difference between the estimates of the
odds ratio and confidence or credibility intervals
between the classical ITC software and the Bayesian
WinBUGS ITC analysis.
For non-vertebral fractures, the evidence was consid-
ered strong and free of bias because of low heterogene-
ity, and similarity of classical results to the Bayesian
analysis. For non-vertebral fractures, the overall odds
r a t i oa c r o s sa l ld r u g sw a sO R=0 . 8 1( 9 5 %C I :0 . 7 7 ,
0.86), (P < 0.01) indicating a protective effect of pharma-
cotherapy (Figure 2). There was no heterogeneity
between types of drugs (I
2 = 0), although low heteroge-
neity (I
2 = 16%) existed for alendronate.
For vertebral fractures, the evidence is considered less
strong than the evidence from non-vertebral fractures
because of increasing heterogeneity (Figure 3), and the
classical analysis having smaller confidence intervals
than the Bayesian analysis. In the classical meta-analysis,
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Figure 1 PRISMA Flow Diagram describing selection process for included studies. PRISMA (Preferred Reporting Items for Systematic
Reviews and Meta-Analyses) Flow Diagram describing selection process for included studies.
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in preventing vertebral fractures, OR = 0.49 (95% CI:
0.41, 0.58), and there was considerable heterogeneity
across all drugs (I
2 = 84%), while there was no heteroge-
neity within drugs. All drugs except one provided signif-
icant predictive effects with the exception being
etidronate, which produced a p-value of 0.10. Conver-
sely, in the Bayesian analysis only risedronate and alen-
dronate had significant odds ratios relative to placebo.
For hip fractures, the evidence is considered less
strong than the evidence from non-vertebral fractures
because of decreased confidence intervals in the classi-
cal analysis (Figure 4). For hip fractures, there was an
overall protective effect against hip fracture for all
drugs, OR = 0.73 (95% CI: 0.63, 0.84), and absence of
heterogeneity (I
2 = 0%). Three drugs reported an inde-
pendent statistical reduction in the rate of hip fracture,
alendronate, OR = 0.62 (95% CI: 0.40, 0.96), denosumab
OR = 0.60 (95% CI: 0.37, 0.98), and risedronate OR =
0.74 (95% CI: 0.58, 0.94). This is in contrast to the
Bayesian analysis where only alendronate reported a sig-
nificant reduction in the odds ratios for hip fracture.
Table 1 Description of Study and Baseline Characteristics for Included Studies
Drug Author Year Study
Duration
(years)
Country/Region Number
of
Centres
Age (yrs)
Mean
(SD)
Years
Menopause
Inclusion
Criteria
Years Since
Menopause
Mean (SD)
BMD Hip
g/cm
2
Mean
(SD)
Prior
Vertebral
Fracture
%
Alendronate Ascott Evans 2003 1 International 18 67.3 (6.6) 3 11.5 (7.3) nr 0
Alendronate Black 1996 3 North America 11 71.0 (5.6) 2 NR (NR) 0.57 (0.07) 100
Alendronate Cummings 1998 4 North America 11 67.6 (6.1) 2 NR (NR) 0.84 (0.13) 0
Alendronate Greenspan 1998 2.5 North America 1 70.0 (4.6) NR NR (NR) 0.57 (0.11) NR
Alendronate Liberman 1995 3 International NR 64.0 (7.0) 5 16.5 (NR) 0.71 (NR) 21
Alendronate Pols 1999 1 International 153 62.8 (7.4) 3 15.9 (1.5) 0.72 (0.08) NR
Denosumab Cummings 2009 4 North America 11 67.7 (6.6) 2 NR (NR) 0.84 (0.13) 0
Etidronate Lyritis 1997 4 Europe 1 72.0 (0.4) NR 25.8 (1.7) 0.57 (NR) 100
Etidronate Meunier 1997 4 Europe 1 52.7 (4.0) 0.5 2.4 91.8) 0.90 (NR) NR
Etidronate Montesorri 1997 3 Europe 2 62.5 (6.2) 1 14.9 (6.1) 0.67 (NR) 29
Etidronate Pacifici 1988 2 U.S.A 1 61.0 (7.8) NR 13.8 (9.5) 0.79 (0.26) 100
Etidronate Pouilles 1997 2 Europe 7 53.8 (3.1) 0.5 2.6 (1.4) 0.96 (NR) NR
Etidronate Storm 1990 3 Europe 1 68.3 (7.3) NR 21.6 (10.2) 0.25 (0.07) 100
Etidronate Watts 1990 2 U.S.A 7 65.1
(13.0)
1 17.9 (16.5) 0.86 (NR) 100
Etidronate Wimalawansa
1998
4 NR NR 64.9 (7.8) NR 15.1 (6.8) 0.83 (NR) 100
Ibandronate Chesnut 2004 3 Europe, U.S.A 73 69.0
(11.0)
5 21 (20.8) 0.78 (NR) 93
Ibandronate Ravn 2002 1 Europe 1 64.5 (5.9) 10 NR (NR) 0.87 (0.13) 28
Ibandronate Adami 2004 1 Europe NR 65.9 (4.5) 5 17.9 (4.0) 0.77 (0.09) 45
Ibandronate Recker 2004 3 Europe NR 67.0 (5.1) 5 NR (NR) 0.80 (0.11) 54
Raloxifene Ettinger 1999 3 International 180 66.1 (6.9) 2 18.6 (7.9) 0.58 (NR) 38
Risedronate Fogelman 2000 2 Europe 13 64.7 (7.2) 1 17.7 (9.4) 0.74 (0.08) 30
Risedronate Harris 1999 3 North America 110 69.0 (7.3) 5 24.0 (9.9) 0.83 (0.16) 81
Risedronate Hooper 2005 2 Australia 11 52.6 (3.3) 0.5 3.9 (5.6) 1.08 (0.12) 18.3
Risedronate McClung 2001 3 International 183 78.0 (9.7) NR 31.8 (19.3) NR (NR) 42
Risedronate Mortenson 1998 2 International 2 51.2 (3.8) 0.5 2.7 91.7) 0.94 (0.11) NR
Risedronate Reginster 2000 3 Europe, Australia 80 71.0 (7.0) 5 24.4 (8.5) 0.79 (0.15) 100
Strontium Meunier 2004 3 Europe,
International
72 69.3 (7.3) 5 43.7 (8.7) 0.68 (0.11) 100
Strontium Reginster 2008 3.5 International 75 76.7 (5.0) 0 28.4 (7.4) 0.55 (NR) 33.5
Teriparatide Neer 2001 2 International 99 69.0 (7.0) 5 21.0 (8.0) 0.82 (0.17) 100
Zoledronate Black 2007 3 U.S.A, Europe 60 73 (5.4) 0 NR (NR) 0.65 (0.91) 36.7
NR: Not reported. BMD: Bone Mineral Density. SD: Standard deviation. U.S.A: United States of America
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because of increasing heterogeneity and differences in
the classical versus Bayesian analysis when drugs were
compared to placebo (Figure 5). For wrist fracture, there
was not an overall protective effect OR = 0.88 (95% CI:
0.77, 1.01), and the heterogeneity was substantial (I
2 =
64%). The only drug that had a significant protective
effect alone was risedronate OR = 0.71 (95% CI: 0.56,
0.89). The analysis of alendronate alone had consider-
able heterogeneity (I
2 = 79%). Removing Cummings and
Greenspan to produce comparable ITC evidence
reduced the heterogeneity to 0% and the odds ratio to
OR = 0.44 (95% CI: 0.30 to 0.67) for alendronate versus
placebo. Removing Cummings and Greenspan produced
an overall odds ratio for all drugs OR = 0.82 (95% CI:
0.71, 0.94: I
2 = 59%).
Adjustment for difference in baseline characteristics
The estimates of the relative efficacy with meta-regression
for each drug versus placebo for each type of fracture were
similar to the estimates of Bayesian analysis for odds
ratios. Unfortunately, when baseline characteristics were
added to the regression equation, there were not enough
studies for the analysis and no estimate could be provided.
This lack of result was created by the addition of the base-
line characteristics age, BMD and rate of prior vertebral
fractures that created multi-collinearity that was detected
by exploded confidence intervals for each drug effect.
When we ran the regression with only the top two drugs
for each fracture along with adding in any of age, BMD or
rates of prior vertebral fractures, the latter effects were sig-
nificant while the drug effects was not significant. This
suggests that the differences across studies in baseline
Table 2 Odds Ratio for Fracture, Indirect Treatment Comparison Results of Drug versus Placebo Classical and Bayesian
analysis
Classical analysis Non-vertebral fracture Vertebral fracture Hip fracture Wrist fracture
Drug vs placebo OR (95% Cr I) Placebo
rate
OR (95% Cr I) Placebo
rate
OR (95% Cr I) Placebo
rate
OR (95% Cr I) Placebo
rate
Alendronate 0.80 (0.68, 0.95) 11.1% 0.51 (0.40, 0.63) 6.7% 0.62 (0.40, 0.96) 1.1% 0.44 (0.30, 0.67) 3.0%
Denosumab 0.80 (0.67, 0.96) 7.5% 0.31 (0.24, 0.40) 7.2% 0.60 (0.37, 0.98) 1.1% NR NR
Etidronate 0.64 (0.31, 1.32) 11.5% 0.59 (0.32, 1.10) 9.7% 0.60 (0.14, 2.66) 2.1% 1.19 (0.37, 3.80) 2.2%
Ibandronate 0.88 (0.71, 1.10) 7.5% 0.49 (0.32, 0.73) 7.5% NR NR NR NR
Raloxifene 0.91 (0.77, 1.07) 9.3% 0.63 (0.50, 0.78) 10.1% 1.12 (0.64, 1.95) 0.7% 0.88 (0.67, 1.15) 3.3%
Risedronate 0.79 (0.69, 0.89) 10.1% 0.59 (0.47, 0.75) 13.3% 0.74 (0.58, 0.94) 2.8% 0.71 (0.56, 0.89) 3.4%
Strontium 0.85 (0.74
(0.98)
14.7% 0.58 (0.50, 0.67) 21.7% 0.66 (1.19) 4.0% 1.59 (1.12, 2.27) 3.2%
Teriparatide 0.62 (0.40, 0.97) 9.7% 0.31 (0.19, 0.52) 14.3% 0.50 (0.09, 2.75) 0.7% 0.50 (0.09, 2.75) 2.4%
Zoledronic Acid 0.74 (0.63, 0.86) 10.0% 0.28 (0.22, 0.35) 10.9% 0.59 (0.83) 2.3% NR NR
All drugs vs
placebo
0.81 (0.77, 0.86) 10.5% 0.49 (0.41, 0.58) 11.0% 0.73 (0.63, 0.84) 1.9% 0.82 (0.71, 0.94) 3.1%
Bayesian analysis Non-vertebral fracture Vertebral fracture Hip fracture Wrist fracture
Drug vs placebo OR (95% Cr I) Prob Effect
size
OR (95% Cr I) Prob Effect
size
OR (95% Cr I) Prob Effect
size
OR (95% Cr I) Prob Effect
size
Alendronate 0.81 (0.66, 0.96) 0.01 16.1 0.51 (0.37, 0.68) <
0.01
25.3 0.59 (0.29, 0.99) 0.10 9.49 0.93 (0.30, 2.64) 0.10 1.80
Denosumab 0.80 (0.60, 1.06) 0.03 10.7 0.31 (0.21, 0.44) 0.20 53.6 0.67 (0.24, 1.47) 0.12 4.76 NR NR NR
Etidronate 0.64 (0.31, 1.27) 0.42 6.4 0.61 (0.29, 1.08 0.01 8.3 1.02 (0.12, 3.91) 0.19 1.01 2.42 (0.25, 10.54) 0.06 0.16
Ibandronate 0.90 (0.69, 1.16) <
0.01
9.3 0.50 (0.29, 0.78) 0.01 16.1 NR NR NR NR NR NR
Raloxifene 0.91 (0.69, 1.20) <
0.01
8.4 0.63 (0.43, 0.90) 0.00 13.4 1.29 (0.45, 2.88) 0.01 1.25 1.76 (0.09, 8.22) 0.15 0.27
Risedronate 0.77 (0.60, 0.91) 0.04 16.4 0.60 (0.45, 0.79) 0.00 19.3 0.78 (0.44, 1.32) 0.01 5.71 0.91 (0.13, 3.27) 0.22 1.37
Strontium 0.86 (0.69, 1.07) <
0.01
12.0 0.59 (0.45, 0.76) <
0.01
21.8 0.98 (0.39, 2.01) 0.01 2.47 3.25 (0.17, 14.89) 0.06 0.08
Teriparatide 0.62 (0.38, 1.02) 0.41 9.9 0.32 (0.17, 0.57) 0.30 29.8 0.71 (0.04, 2.90) 0.44 1.93 1.23 (0.05, 5.64) 0.41 0.57
Zoledronic Acid 0.74 (0.56, 0.97) 0.08 12.9 0.28 (0.19, 0.40) 0.40 66.2 0.65 (0.25, 1.34) 0.11 5.53 NR NR NR
OR (95% Cr I): Odds ratio (95% Credibility Interval). Prob: probability of that drug being most efficacious.
Effect size evaluated as Odds ratio divided by corresponding standard error. NR: Not reported.
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Page 7 of 16characteristics contribute more to variation in odds ratio
of fractures across studies than changes in the drugs.
Discussion
The objective was to update the literature on the rela-
tive efficacy of different osteoporosis medications to pre-
vent four types of osteoporosis-related fractures. Based
on the combination of effect size and probability of
being most efficacious, teriparatide zoledronic acid and
denosumab are consistently ranked highest for reducing
non-vertebral and vertebral fractures, the two most
common types of fractures
Etidronate is also ranked high on probability of being
most efficacious but there are reservations with this
result. First, etidronate does not have a statistically sig-
nificant odds ratio versus placebo for non-vertebral
Table 3 Odds Ratio for Fracture, Indirect Treatment Comparison between drugs (Bayesian analysis)
Non-vertebral fracture Vertebral fracture Hip fracture Wrist fracture
OR (95% CrI) NNT OR (95% CrI) NNT OR (95% CrI) NNT OR (95% CrI) NNT
Denosumab vs Alendronate 0.99 (0.72, 1.42) 1,063 0.63 (0.38, 0.97) 26 1.30 (0.38, 3.35) -180 NR NR
Denosumab vs Etidronate 1.26 (0.59, 2.69) -42 0.58 (0.26, 1.15) 23 1.43 (0.13, 5.97) -126 NR NR
Denosumab vs Ibandronate 0.89 (0.61, 1.31) 96 0.67 (0.35, 1.19) 30 NR NR NR NR
Denosumab vs Raloxifene 0.87 (0.59, 1.30) 81 0.51 (0.29, 0.83) 20 0.71 (0.14, 1.89) 184 NR NR
Denosumab vs Risedronate 1.04 (0.76, 1.54) -267 0.53 (0.32, 0.82) 21 0.94 (0.27, 2.24) 893 NR NR
Denosumab vs Teriparatide 1.29 (0.73, 2.26) -38 1.06 (0.50, 1.99) -169 3.24 (0.17, 16.89) -25 NR NR
Denosumab vs Zoledronic Acid 1.08 (0.73, 1.62) -134 1.16 (0.66, 1.88) -65 1.36 (0.30, 3.48) -150 NR -14
Etidronate vs Alendronate 0.79 (0.38, 1.61) 50 1.22 (0.54, 2.28) -48 1.91 (0.20, 7.43) -60 3.48 (0.22, 16.27) NR
Ibandronate vs Alendronate 1.13 (0.82, 1.60) -83 1.00 (0.54, 1.69) 20,428 NR NR NR NR
Ibandronate vs Etidronate 1.44 (0.68, 3.06) -25 0.92 (0.37, 1.95) 121 NR NR NR -22
Raloxifene vs Alendronate 1.12 (0.82, 1.55) -90 1.28 (0.78, 1.98) -38 2.47 (0.71, 6.55) -38 2.60 (0.08, 11.84) -39
Raloxifene vs Etidronate 1.41 (0.68, 2.96) -27 1.17 (0.53, 2.29) -62 2.76 (0.24, 11.66) -32 1.87 (0.03, 9.82) NR
Raloxifene vs Ibandronate 1.02 (0.70, 1.49) -533 1.36 (0.71, 2.38) -29 NR NR NR -108
Risedronate vs Alendronate 0.95 (0.71, 1.23) 212 1.21 (0.79, 1.79) -50 1.47 (0.62, 3.31) -115 1.31 (0.10, 5.21) 3,328
Risedronate vs Etidronate 1.19 (0.57, 2.49) -57 1.11 (0.52, 2.18) -95 1.65 (0.18, 6.64) -84 0.99 (0.03, 4.68) NR
Risedronate vs Ibandronate 0.85 (0.60, 1.15) 70 1.29 (0.71, 2.19) -36 NR NR NR -25
Risedronate vs Raloxifene 0.84 (0.57, 1.15) 65 0.98 (0.61, 1.51) 622 0.79 (0.23, 1.96) 254 2.39 (0.05, 11.67) -10
Strontium vs Alendronate 1.06 (0.81, 1.44) -178 1.18 (0.78, 1.71) -58 1.89 (0.61, 4.70) -61 4.78 (0.14, 21.71) NR
Strontium vs Denosumab 1.08 (0.75, 1.53) -134 1.95 (1.20, 2.99) -12 1.98 (0.44, 5.03) -56 NR -13
Strontium vs Etidronate 1.36 (0.65, 2.86) -31 1.08 (0.51, 2.07) -127 2.09 (0.20, 8.75) -50 3.72 (0.05, 17.44) NR
Strontium vs Ibandronate 0.95 (0.69, 1.34) 212 1.26 (0.70, 2.15) -40 NR NR NR -4
Strontium vs Raloxifene 0.94 (0.66, 1.34) 176 0.96 (0.60, 1.46) 243 1.03 (0.23, 2.66) -1,789 10.85 (0.08, 41.99) -6
Strontium vs Risedronate 1.12 (0.86, 1.57) -90 0.99 (0.67, 1.43) 1,890 1.37 (0.44, 3.10) -146 8.00 (0.15, 38.56) -3
Strontium vs Teriparatide 1.38 (0.80, 2.35) -29 1.99 (0.95, 3.66) -11 4.92 (0.26, 24.44) -15 19.69 (0.12, 80.47) NR
Strontium vs Zoledronic Acid 1.17 (0.83, 1.66) -64 2.17 (1.34, 3.34) -10 1.93 (0.47, 4.98) -59 NR -49
Teriparatide vs Alendronate 0.77 (0.46, 1.31) 45 0.65 (0.31, 1.26) 28 1.35 (0.07, 5.71) -154 1.69 (0.04, 8.09) -102
Teriparatide vs Etidronate 0.98 (0.40, 2.30) 531 0.70 (0.39, 1.45) 24 1.54 (0.03, 9.01) -100 1.33 (0.02, 6.65) NR
Teriparatide vs Ibandronate 0.69 (0.40, 1.22) 33 0.53 (0.25, 0.98) 32 NR NR NR -13
Teriparatide vs Raloxifene 0.68 (0.39, 1.19) 32 0.55 (0.26, 0.98) 21 0.76 (0.03, 3.27) 223 3.68 (0.02, 15.16) -16
Teriparatide vs Risedronate 0.81 (0.49, 1.41) 55 0.55 (0.34, 1.04) 22 1.00 (0.05, 4.18) NR 3.20 (0.04, 14.42) NR
Zoledronic Acid vs Alendronate 0.91 (0.66, 1.30) 117 0.56 (0.34, 0.88) 22 1.24 (0.39, 3.16) -225 NR NR
Zoledronic Acid vs Etidronate 1.16 (0.55, 2.45) -68 0.52 (0.23, 1.04) 20 1.38 (0.12, 5.70) -142 NR NR
Zoledronic Acid vs Ibandronate 0.82 (0.56, 1.19) 58 0.60 (0.31, 1.06) 25 NR NR NR NR
Zoledronic Acid vs Raloxifene 0.81 (0.54, 1.19) 55 0.46 (0.26, 0.74) 18 0.68 (0.15, 1.78) 167 NR NR
Zoledronic Acid vs Risedronate 0.96 (0.71, 1.41) 265 0.48 (0.29, 0.74) 18 0.91 (0.28, 2.07) 595 NR NR
Zoledronic Acid vs Teriparatide 1.19 (0.68, 2.08) -57 0.95 (0.45, 1.83) 216 3.11 (0.17, 16.12) -26 NR NR
NR: Not reported. Results are reported as Odds ratio.
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Page 8 of 16Figure 2 Forest plot non vertebral fractures. Odds ratio of non vertebral fractures for drugs versus placebo using Classical meta-analysis
approach.
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Page 9 of 16Figure 3 Forest plot vertebral fractures. Odds ratio of vertebral fractures for drugs versus placebo using Classical meta-analysis approach.
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Page 10 of 16Figure 4 Forest plot hip fractures. Odds ratio of hip fractures for drugs versus placebo using Classical meta-analysis approach.
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Page 11 of 16Figure 5 Forest plot wrist fractures. Odds ratio of wrist fractures for drugs versus placebo using Classical meta-analysis approach.
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Page 12 of 16fracture, but was ranked highest for being efficacious.
T h eh i g h e rr a n k i n gm a yb ed u et oaw i d ec o n f i d e n c e
interval that covers a lower region of odds ratio creating
a favourable relative result over that region of low odds
ratio. This suggests a limitation with this analysis where
a requirement may be that the odds ratio for different
drugs should have similar widths. A second caution with
the results for etidronate is that the trials were small
resulting in small effect sizes and the trials were con-
ducted prior to the year 2000. This suggests that there
is a lack of current strong evidence for the efficacy of
etidronate versus placebo. As a result of these two lim-
itations, this analysis suggests that etidronate should not
be considered among the most efficacious drugs based
on current evidence.
In addition, the number needed to treat analysis that
treating as few as 10 patients with teriparatide, zoledronic
acid or denosumab will produce 1 less fracture than if the
patients were on other drugs.
This work updates the most recent study for ITC ana-
lysis in osteoporosis medications which looked at ver-
tebral, hip and nonvertebral nonhip fractures [13] for
five drugs, zoledronic acid, alendronate, ibandronate,
risedronate and etidronate. Based on that analysis zole-
dronic acid had a 0.79 probability of being the most effi-
cacious for vertebral fractures. In our analysis,
teriparatide (0.40) and etidronate (0.40) had the highest
probability of being the most efficacious. In our analysis,
we included more studies for etidronate, alendronate,
and risedronate in addition to adding denosumab, ralox-
ifene, strontium and teriparatide. Similarly, the earlier
work reported that zoledronic acid had the highest
probability of preventing hip fractures, while our analy-
sis indicates the most efficacious drugs are teriparatide
(0.44), and that zoledronic acid (0.11), etidronate (0.19),
denosumab (0.12) and alendronate (0.10) could be the
most efficacious treatment. One key difference between
inclusions of different studies was that we analyzed
wrist fractures specifically while the earlier work
reported on nonvertebral nonhip fractures [13]. We
report that risedronate does have a high probability of
being most efficacious similar to earlier work but we
estimated that teriparatide has the highest probability of
preventing wrist fractures (0.44).
The other objective of this analysis was to compare
the results across two statistical methods. The first
method was based on Bayesian ITC analysis in Win-
BUGS, and the second method was the results from
classical Bucher analysis with ITC specific software. The
estimates differed only by the second decimal place
when the results were statically significant. However,
t h e r ea r ek e yd i f f e r e n c e si nt h ei n t e r p r e t a t i o no ft h e
results. Based on the classical analysis we generated con-
fidence intervals around the odds ratio and provided a
test of association. In the Bayesian analysis, we gener-
ated a posterior distribution of the credible intervals for
the true values of the odds ratio. In this analysis these
values are similar, indicating that the priors used in the
analysis were uninformative.
The analysis is limited in that the results are based on
ITC comparisons. However, a recent review of the
results of DTC and ITC analysis, described that out of
44 meta-analysis that were available with studies for
meta-analysis by ITC and studies for meta-analysis by
DTC, the DTC was similar in all but 3 cases to the ITC
estimates for the same drugs and outcomes [9]. Of the 3
cases where the results were statistically different, 2
cases had the relative clinical benefit in the same direc-
tion while the third had differences in dosage regime in
the studies. This result was also reported by Bucher in
1997 [10] where the ITC results were similar in direc-
tion as the DTC estimates. In addition, Bucher and
Song both reported that the magnitude of the ITC
results was larger between comparators than DTC com-
parisons, and the level of significance between compara-
tors was less in ITC than DTC. In our ITC analysis,
non-significant differences were estimated between
drugs but the true effect between drugs may be even
smaller.
The other assessment of strength of evidence in the
indirect comparisons beyond looking at different classi-
cal versus Bayesian analysis was to look at heterogeneity
within drugs and across drugs. The heterogeneity
between comparators and heterogeneity within one
comparator was small, with the exception of alendronate
for wrist fractures. This heterogeneity was explained by
two studies [28,29] for wrist fractures. These studies did
not contribute to heterogeneity in the meta-analysis of
vertebral fractures and non-vertebral fractures. However,
these two studies included the one study [28] that was
the longest study with duration of 4 years with a low
risk patients and the largest study for alendronate, while
the other study [29] was small single centre study with
duration of 4 years with low risk patients and the largest
study.
The interpretation of the heterogeneity, although not a
major feature in this analysis, is an important factor for
ITC analysis. Increased heterogeneity can be caused by
differences in inclusion criteria or study design such as
length of follow-up. These are also important factors for
consideration for analysis of DTC studies [20]. Three
studies assessed the effect of patient characteristics to
explain the level of heterogeneity in ITC analysis. In 2
studies [56,57] no baseline variables were significant
while in the other study [58] the year of the study and
baseline risk affected heterogeneity. Both of these factors
may have also affected heterogeneity if the studies were
randomized with an active comparator. In our analysis,
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baseline characteristics because of a low number of stu-
dies for each drug [22]. In addition, because of the high
heterogeneity in the estimates of odds ratios for wrist
fractures, the evidence for wrist fractures should be con-
sidered weak.
ITC is becoming a useful tool in the absence of DTC
comparisons and increasing transparency of ITC analysis
builds confidence for the evidence. In a review of 88
ITC analyses, many of the studies could have increased
the believability of their results [9] but the missed ele-
ments would also concern DTC analysis. These include
incomplete searches or not assessing heterogeneity
within a comparator. In 40/88 analysis there was no spe-
cific searches for active comparison studies to allow the
comparison to the ITC evidence. For osteoporosis, this
search was conducted and we found no published meta-
analysis of DTC evidence. In the future stronger evi-
dence may come from head-to-head studies but this is
unlikely, because based on this analysis differences
between comparators are not significant and studies
would require very large sample sizes. Alternatively, the
treatment analysis could come for pooling patient level
data to compare the effects directly but this is unlikely
due to propriety, and this analysis would diminish the
benefits of randomization.
Conclusion
In light of the lack of DTC evidence, the ITC analysis of
RPCTs may be the strongest evidence that will be avail-
able that answers the important clinical question of
determining the most efficacious treatment for prevent-
ing fractures. In this analysis, teriparatide, zoledronic
acid and denosumab have the highest probabilities of
being most efficacious for non-vertebral and vertebral
fractures, and having the greatest effect sizes. The esti-
mates from indirect comparisons were robust to differ-
ences in methodology.
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